Back to Report Store Home

Global Neurodegenerative Drugs Market to 2022 – Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • Published: Dec-2016
  • Report Code: GBIHC425MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 10

2.1 Therapy Area Introduction 10

2.1.1 Alzheimer’s Disease 10

2.1.2 Parkinson’s Disease 11

2.1.3 Huntington’s Disease 11

2.1.4 Amyotrophic Lateral Sclerosis 12

2.1.5 Multiple Sclerosis 13

2.2 Symptoms 14

2.3 Etiology and Pathophysiology 15

2.3.1 Pathophysiology 18

2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 22

2.4.1 Alzheimer’s Disease 23

2.4.2 Parkinson’s Disease 24

2.4.3 Huntington’s Disease 25

2.4.4 Amyotrophic Lateral Sclerosis 26

2.4.5 Multiple Sclerosis 27

2.5 Co-morbidities and Complications 28

2.6 Treatment 29

2.6.1 Alzheimer’s Disease 29

2.6.2 Parkinson’s Disease 30

2.6.3 Huntington’s Disease 33

2.6.4 Amyotrophic Lateral Sclerosis 33

2.6.5 Multiple Sclerosis 33

3 Key Marketed Products 35

3.1 Overview 35

3.2 Tecfidera (dimethyl fumarate) – Biogen 35

3.3 Copaxone (glatiramer acetate) – Teva 37

3.4 Tysabri (natalizumab) – Biogen 39

3.5 Gilenya (fingolimod hydrochloride) – Novartis 41

3.6 Avonex (interferon beta-1a) – Biogen 43

3.7 Plegridy (peginterferon beta-1a) – Biogen 44

3.8 Namenda/Memary/Ebixa/Axura/Namenda XR (memantine hydrochloride/memantine hydrochloride ER) – Merz Pharma/Lundbeck/Forest/Daiichi Sankyo 46

3.9 Nuplazid (pimavanserin tartrate) – Acadia 48

4 Pipeline Landscape Assessment 51

4.1 Pipeline Development Landscape 51

4.2 Molecular Targets in the Pipeline 54

4.3 Clinical Trials 57

4.3.1 Failure Rate 57

4.3.2 Clinical Trial Duration 61

4.3.3 Clinical Trial Size 65

4.3.4 Aggregate Clinical Program Size 69

4.4 Assessment of Key Pipeline Products 72

4.4.1 Ocrelizumab – Roche 72

4.4.2 Ozanimod – Celgene 74

4.4.3 Solanezumab – Eli Lilly 75

4.4.4 Crenezumab – Roche 76

4.4.5 Tirasemtiv – Cytokinetics 78

4.4.6 CVT-301 (Levodopa) – Acorda Therapeutics 79

4.5 5.5 Conclusion 80

5 Multi-scenario Market Forecast to 2022 82

5.1 Overall Market Size 82

5.2 Generic Penetration 84

5.3 Revenue Forecast by Molecular Target 84

5.3.1 Immunomodulators (interferon receptor/S1PR1/MHC II/IL-2 receptor/cells expressing B lymphocyte antigen CD20/glucocorticoid receptor) 85

5.3.2 Neuromodulators (acetylcholinesterase/dopamine receptor/5HTA receptor) 85

5.3.3 Amyloid Inhibitors (Amyloid Beta Inhibitors) 86

5.3.4 APP inhibitors (BACE) 87

6 Company Analysis and Positioning 88

6.1 Revenue and Market Share Analysis by Company 89

6.1.1 Biogen – Will the Patent Expiration of Tysabri Cause a Loss in Market Size? 94

6.1.2 Novartis – Gradual Decline in Revenue due to Gilenya Patent Expiration 95

6.1.3 Roche – Approval of Ocrelizumab to Drive Market Size 96

6.1.4 Sanofi – Aubagio and Lemtrada to Become Blockbuster Drugs 97

6.1.5 Teva – Gradual Decline in Revenue due to Patent Expiration of Products 98

6.1.6 Acadia – Newly Approved Nuplazid Expected to Achieve Blockbuster Status in Forecast Period 99

6.1.7 AbbVie – Pipeline Product Approval to Significantly Increase CAGR 100

6.1.8 Eli Lilly – Solanezumab to Achieve Blockbuster Status following its Approval 101

6.1.9 Celgene – Its First Product in Neurodegenerative Disorder Market to Reach Blockbuster Status in Forecast Period 102

6.1.10 Lundbeck – Approval of Idalopirdine to Offset Loss in Revenue Caused by Patent Expiration of Azilect 103

6.2 Company Landscape 104

6.3 Marketed and Pipeline Portfolio Analysis 105

7 Strategic Consolidations 107

7.1 Licensing Deals 107

7.1.1 Deals by Region, Year and Value 107

7.1.2 Deals by Stage of Development and Value 109

7.1.3 Deals by Molecule Type, Mechanism of Action and Value 110

7.1.4 Table for Licensing Deals Valued above $100m 112

7.2 Co-development Deals 115

7.2.1 Deals by Region, Year and Value 115

7.2.2 Deals by Stage of Development and Value 117

7.2.3 Deals by Molecule Type, Mechanism of Action and Value 118

7.2.4 Table for Co-development Deals Valued above $100m 120

8 Appendix 122

8.1 References 122

8.2 Abbreviations 132

8.3 Disease List 133

8.4 Methodology 133

8.4.1 Coverage 133

8.4.2 Secondary Research 134

8.4.3 Market Size and Revenue Forecasts 134

8.4.4 Pipeline Analysis 134

8.4.5 Competitive Landscape 135

8.5 Contact Us 135

8.6 Disclaimer 135

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards